Many of Australia’s top brokers have been busy adjusting their financial models again, leading to the release of a large number of broker notes this week.
Three buy ratings that have caught my eye are summarised below. Here’s why brokers think these ASX shares are in the buy zone:
BHP Group Ltd (ASX: BHP)
According to a note out of Goldman Sachs, its analysts have upgraded this mining giant’s shares to a buy rating with a $41.90 price target after reviewing its five key greenfield oil projects. Goldman believes that these projects could boost the company’s oil production by 50% to 180 Mmboe by FY 2030. In addition to this, the broker continues to expect iron ore prices to stay higher for longer due to a potential deficit in 2020. It believes restocking from Chinese steel mills will drive iron ore back to beyond US$100 a tonne during the fourth quarter. I agree with Goldman on BHP and feel it would be a great option for investors looking for exposure to the resources sector.
Ramsay Health Care Limited (ASX: RHC)
A note out of Citi reveals that its analysts have upgraded this private hospital operator’s shares to a buy rating with a $74.00 price target. According to the note, although the broker notes that the Australian market is still facing a number of headwinds, it expects Ramsay to benefit from market share gains. In addition to this, it sees a lot of positives in the recent Capio acquisition and appears confident that it will support its growth in FY 2020. Whilst I think Ramsay is a high quality company, I’m holding off an investment until trading conditions improve.
Syrah Resources Ltd (ASX: SYR)
Analysts at Credit Suisse have held firm with their outperform rating but trimmed the price target on this graphite producer’s shares to $2.30 following its recent production downgrade. According to the note, whilst the decline in graphite prices is disappointing and appears to have been driven partly by increased supply in China, the broker remains optimistic on the long term due to its bullish view on demand for lithium-ion battery technology. Whilst I think that Credit Suisse makes a fair point, I would suggest investors wait for graphite prices to rebound materially before considering an investment.
Looking for more buy ideas? Then check out these top blue chips that have been rated as buys.
You’re invited! For a limited time, The Motley Fool Australia is giving away an urgent new investment report detailing our 3 TOP BLUE CHIP SHARES to own in 2019.
So if you like trustworthy, stable, high-performing companies that pay fat fully franked dividends – we’ve got you covered!
Stock #1 is a beloved old Australian company turning its attention to high-margin businesses... and rapidly returning cash to shareholders with its hefty dividend...
While Stock #2 is an online powerhouse that’s rapidly gaining market share all around the globe... poised for years (or even decades) of tremendous growth...
Even better, Stock #3 offers a whopping 6.5% grossed-up dividend! Which beats the rates on term deposits right out of the water – and offers the potential for capital gains, too.
You can discover all three shares inside our new report right now. To scoop up your FREE copy, simply click the link below right now. But you will want to hurry – this free report is available for a LIMITED TIME ONLY!
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ramsay Health Care Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.